Livforsakringsbolaget Skandia Omsesidigt Purchases Shares of 504 Revvity, Inc. (NYSE:RVTY)

Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Revvity, Inc. (NYSE:RVTY) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 504 shares of the company’s stock, valued at approximately $55,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gladius Capital Management LP lifted its holdings in shares of Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after acquiring an additional 106 shares during the period. CENTRAL TRUST Co bought a new position in shares of Revvity during the 4th quarter worth about $27,000. ORG Partners LLC bought a new position in shares of Revvity during the 4th quarter worth about $32,000. JTC Employer Solutions Trustee Ltd bought a new position in shares of Revvity during the 4th quarter worth about $33,000. Finally, Desjardins Global Asset Management Inc. bought a new position in shares of Revvity during the 4th quarter worth about $37,000. 86.65% of the stock is owned by institutional investors.

Insider Buying and Selling at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares in the company, valued at approximately $9,677,288.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Revvity Trading Up 1.5 %

RVTY opened at $100.86 on Friday. The company has a current ratio of 2.07, a quick ratio of 1.77 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $12.46 billion, a PE ratio of 18.34, a PEG ratio of 2.59 and a beta of 1.09. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $135.67. The firm has a 50-day moving average price of $104.78 and a two-hundred day moving average price of $101.64.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.10. The firm had revenue of $695.90 million during the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. As a group, equities analysts anticipate that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Thursday, April 18th. Revvity’s payout ratio is presently 5.09%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Stifel Nicolaus raised their price objective on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Barclays lifted their price target on shares of Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Raymond James lifted their price target on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $88.00 to $125.00 in a report on Thursday, January 4th. Finally, UBS Group downgraded shares of Revvity from a “buy” rating to a “neutral” rating and lifted their price target for the company from $105.00 to $125.00 in a report on Tuesday, January 16th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $118.91.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.